A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis

Jin Endo, Motoaki Sano, Yasuhiro Izumiya, Kenichi Tsujita, Kazufumi Nakamura, Nobuhiro Tahara, Koichiro Kuwahara, Takayuki Inomata, Mitsuharu Ueda, Yoshiki Sekijima, Yukio Ando, Hiroyuki Tsutsui, Mitsuaki Isobe, Keiichi Fukuda

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Transthyretin cardiac amyloidosis is a progressive and life-threating disease that is significantly underdiagnosed, and the actual number of patients with the disease is presently unknown. Accumulation of wild-type transthyretin-derived amyloid in the heart is a common finding in very elderly patients. Recent clinical trials demonstrated that tafamidis reduced all-cause death and the number of cardiovascular hospitalizations when compared with placebo. The Japanese Ministry of Health, Labour and Welfare approved tafamidis (Vyndaqel®, Pfizer Inc.) for the treatment of cardiomyopathy caused by both wild-type and mutated transthyretin-derived amyloidoses. This scientific statement on transthyretin-derived cardiac amyloidosis summarizes the conditions for reimbursement of the cost of tafamidis therapy, and the institutional and physician requirements for the introduction of tafamidis.

Original languageEnglish
Pages (from-to)15-17
Number of pages3
JournalCirculation Journal
Volume84
Issue number1
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Prealbumin
Amyloidosis
Cardiomyopathies
Amyloid
Cause of Death
Hospitalization
Placebos
Clinical Trials
Physicians
Costs and Cost Analysis
Amyloidosis, Hereditary, Transthyretin-Related
tafamidis
Health
Therapeutics

Keywords

  • Amyloid
  • ATTR cardiac amyloidosis
  • Japanese Circulation Society
  • Japanese Ministry of Health, Labour and Welfare (JMHLW)
  • Tafamidis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis. / Endo, Jin; Sano, Motoaki; Izumiya, Yasuhiro; Tsujita, Kenichi; Nakamura, Kazufumi; Tahara, Nobuhiro; Kuwahara, Koichiro; Inomata, Takayuki; Ueda, Mitsuharu; Sekijima, Yoshiki; Ando, Yukio; Tsutsui, Hiroyuki; Isobe, Mitsuaki; Fukuda, Keiichi.

In: Circulation Journal, Vol. 84, No. 1, 01.01.2019, p. 15-17.

Research output: Contribution to journalReview article

Endo, J, Sano, M, Izumiya, Y, Tsujita, K, Nakamura, K, Tahara, N, Kuwahara, K, Inomata, T, Ueda, M, Sekijima, Y, Ando, Y, Tsutsui, H, Isobe, M & Fukuda, K 2019, 'A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis', Circulation Journal, vol. 84, no. 1, pp. 15-17. https://doi.org/10.1253/circj.CJ-19-0811
Endo, Jin ; Sano, Motoaki ; Izumiya, Yasuhiro ; Tsujita, Kenichi ; Nakamura, Kazufumi ; Tahara, Nobuhiro ; Kuwahara, Koichiro ; Inomata, Takayuki ; Ueda, Mitsuharu ; Sekijima, Yoshiki ; Ando, Yukio ; Tsutsui, Hiroyuki ; Isobe, Mitsuaki ; Fukuda, Keiichi. / A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis. In: Circulation Journal. 2019 ; Vol. 84, No. 1. pp. 15-17.
@article{52124a8ac3584b60a8db6e9c98637a95,
title = "A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis",
abstract = "Transthyretin cardiac amyloidosis is a progressive and life-threating disease that is significantly underdiagnosed, and the actual number of patients with the disease is presently unknown. Accumulation of wild-type transthyretin-derived amyloid in the heart is a common finding in very elderly patients. Recent clinical trials demonstrated that tafamidis reduced all-cause death and the number of cardiovascular hospitalizations when compared with placebo. The Japanese Ministry of Health, Labour and Welfare approved tafamidis (Vyndaqel{\circledR}, Pfizer Inc.) for the treatment of cardiomyopathy caused by both wild-type and mutated transthyretin-derived amyloidoses. This scientific statement on transthyretin-derived cardiac amyloidosis summarizes the conditions for reimbursement of the cost of tafamidis therapy, and the institutional and physician requirements for the introduction of tafamidis.",
keywords = "Amyloid, ATTR cardiac amyloidosis, Japanese Circulation Society, Japanese Ministry of Health, Labour and Welfare (JMHLW), Tafamidis",
author = "Jin Endo and Motoaki Sano and Yasuhiro Izumiya and Kenichi Tsujita and Kazufumi Nakamura and Nobuhiro Tahara and Koichiro Kuwahara and Takayuki Inomata and Mitsuharu Ueda and Yoshiki Sekijima and Yukio Ando and Hiroyuki Tsutsui and Mitsuaki Isobe and Keiichi Fukuda",
year = "2019",
month = "1",
day = "1",
doi = "10.1253/circj.CJ-19-0811",
language = "English",
volume = "84",
pages = "15--17",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "1",

}

TY - JOUR

T1 - A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis

AU - Endo, Jin

AU - Sano, Motoaki

AU - Izumiya, Yasuhiro

AU - Tsujita, Kenichi

AU - Nakamura, Kazufumi

AU - Tahara, Nobuhiro

AU - Kuwahara, Koichiro

AU - Inomata, Takayuki

AU - Ueda, Mitsuharu

AU - Sekijima, Yoshiki

AU - Ando, Yukio

AU - Tsutsui, Hiroyuki

AU - Isobe, Mitsuaki

AU - Fukuda, Keiichi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Transthyretin cardiac amyloidosis is a progressive and life-threating disease that is significantly underdiagnosed, and the actual number of patients with the disease is presently unknown. Accumulation of wild-type transthyretin-derived amyloid in the heart is a common finding in very elderly patients. Recent clinical trials demonstrated that tafamidis reduced all-cause death and the number of cardiovascular hospitalizations when compared with placebo. The Japanese Ministry of Health, Labour and Welfare approved tafamidis (Vyndaqel®, Pfizer Inc.) for the treatment of cardiomyopathy caused by both wild-type and mutated transthyretin-derived amyloidoses. This scientific statement on transthyretin-derived cardiac amyloidosis summarizes the conditions for reimbursement of the cost of tafamidis therapy, and the institutional and physician requirements for the introduction of tafamidis.

AB - Transthyretin cardiac amyloidosis is a progressive and life-threating disease that is significantly underdiagnosed, and the actual number of patients with the disease is presently unknown. Accumulation of wild-type transthyretin-derived amyloid in the heart is a common finding in very elderly patients. Recent clinical trials demonstrated that tafamidis reduced all-cause death and the number of cardiovascular hospitalizations when compared with placebo. The Japanese Ministry of Health, Labour and Welfare approved tafamidis (Vyndaqel®, Pfizer Inc.) for the treatment of cardiomyopathy caused by both wild-type and mutated transthyretin-derived amyloidoses. This scientific statement on transthyretin-derived cardiac amyloidosis summarizes the conditions for reimbursement of the cost of tafamidis therapy, and the institutional and physician requirements for the introduction of tafamidis.

KW - Amyloid

KW - ATTR cardiac amyloidosis

KW - Japanese Circulation Society

KW - Japanese Ministry of Health, Labour and Welfare (JMHLW)

KW - Tafamidis

UR - http://www.scopus.com/inward/record.url?scp=85077222802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077222802&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-19-0811

DO - 10.1253/circj.CJ-19-0811

M3 - Review article

C2 - 31735731

AN - SCOPUS:85077222802

VL - 84

SP - 15

EP - 17

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 1

ER -